Search results for: 'disease burden'

According to the National Institute of Health (NIH), there are more than 80 types of autoimmune diseases, of which less than 30 are diagnosable. Being 1 of the top 10 causes of death in the United States, there is a critical need in the market for the diagnosis and the treatment of both systemic diseases, such as lupus and rheumatoid arthritis, as ...

This report is a thorough examination of the current and future face of therapy for neurodegenerative diseases, such as Alzheimer's and Parkinson's. It articulates important growth drivers (e.g., precision medicine, AI paradigm for diagnostics, and the transformational megatrends of aging populations) and barriers they will face (e.g., the nature o...

The rising global prevalence of neurodegenerative diseases (NDDs) is driving the shift from symptom-to-disease-modifying therapeutics that target unique pathological mechanisms, such as protein misfolding, neuroinflammation, and synaptic dysfunction, and customizing treatment based on unique genetic profiles, disease subtypes, and distinct biomarke...

22 Aug 2024  |  Global  |  Technology Research

Pipeline Assessment for Cardiovascular Diseases

Advanced Drug Modalities Fuel Cardiovascular Therapeutics Future Growth Potential

Infographics

×

Globally, CVD is the leading cause of death, with resurgence in higher-income countries and higher prevalence in low- and middle-income countries. While there have been many advancements made to this indication using wearables and advanced diagnostics and devices, growth in therapeutics has been veiled. Traditional pharmacotherapy faces the drawbac...

Mitochondria are vital structures in the human body, and they play an active role in several processes. They are widely recognized as the powerhouses of the cell because of their essential function in energy production. In addition, mitochondria have a significant impact on several functions of the human body; as a result, any dysfunction in mitoch...

Rare diseases pose a global burden to healthcare despite making up a very small fraction of the global disease landscape. Most treatment options for rare diseases focus on maintaining the disease symptoms, rather than a disease-modifying approach. To address this unmet need, RNA therapies are emerging as disease-modifying approaches addressing the ...

Since the onset of the COVID-19 pandemic, molecular diagnostics mergers/acquisition transactions and product launches for infectious disease testing are indicating a pivot toward a new direction or an enhancement of portfolios. The emergence of saliva sample testing and the transition to PCR-based syndromic and direct-to-consumer testing for respir...

14 Feb 2022  |  Global  |  Market Research

Global Neurovascular Disease Management Growth Opportunities

AI-based Triaging and Simulation Technology to Aid Expansion of Neurointerventional Stroke Management Procedures

Infographics

×

The global prevalence of stroke is estimated to be about 100 million as of 2021. In the past 30 years, improvements in stroke prevention, acute treatment, and neuro-rehabilitation have contributed to a significant reduction in the burden of stroke in high-income countries. Neurovascular solutions companies recognize the importance of optimized solu...

19 Jun 2024  |  Global  |  Technology Research

Molecular Diagnostics for Neurodegenerative Diseases: Technology Growth Opportunities, 2024 2028

Leveraging integrated and point-of-care diagnostics with multiomics represents the most promising growth opportunity to advance molecular diagnostics for neurodegenerative diseases

Infographics

×

Neurodegenerative diseases (NDD) pose significant challenges to healthcare systems and affect millions of people worldwide, making early detection crucial. While the current diagnostic strategy is predominantly brain imaging techniques, it is not performed until symptoms are more pronounced. Subtle changes occurring in neural cells during early pro...